Thrombin Generation and Cancer: Contributors and Consequences

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2019 Jan 19

PMID 30654498

Citations 34

Authors

Caroline J Reddel

Chuen Wen Tan

Vivien M Chen

Affiliations

Soon will be listed here.

Abstract

The high occurrence of cancer-associated thrombosis is associated with elevated thrombin generation. Tumour cells increase the potential for thrombin generation both directly, through the expression and release of procoagulant factors, and indirectly, through signals that activate other cell types (including platelets, leukocytes and erythrocytes). Furthermore, cancer treatments can worsen these effects. Coagulation factors, including tissue factor, and inhibitors of coagulation are altered and extracellular vesicles (EVs), which can promote and support thrombin generation, are released by tumour and other cells. Some phosphatidylserine-expressing platelet subsets and platelet-derived EVs provide the surface required for the assembly of coagulation factors essential for thrombin generation in vivo. This review will explore the causes of increased thrombin production in cancer, and the availability and utility of tests and biomarkers. Increased thrombin production not only increases blood coagulation, but also promotes tumour growth and metastasis and as a consequence, thrombin and its contributors present opportunities for treatment of cancer-associated thrombosis and cancer itself.

Citing Articles

The Basic Principles of Pathophysiology of Venous Thrombosis.

Schulman S, Makatsariya A, Khizroeva J, Bitsadze V, Kapanadze D Int J Mol Sci. 2024; 25(21).

PMID: 39519000 PMC: 11547114. DOI: 10.3390/ijms252111447.

Glutamine metabolism-related genes predict the prognostic risk of acute myeloid leukemia and stratify patients by subtype analysis.

Zhou J, Zhang N, Zuo Y, Xu F, Cheng L, Fu Y Hereditas. 2024; 161(1):35.

PMID: 39300580 PMC: 11414284. DOI: 10.1186/s41065-024-00338-8.

Haemostatic Gene Expression in Cancer-Related Immunothrombosis: Contribution for Venous Thromboembolism and Ovarian Tumour Behaviour.

Tavares V, Savva-Bordalo J, Rei M, Liz-Pimenta J, Assis J, Pereira D Cancers (Basel). 2024; 16(13).

PMID: 39001418 PMC: 11240748. DOI: 10.3390/cancers16132356.

Inhibitory effect of recombinant tyrosine‑sulfated madanin‑1, a thrombin inhibitor, on the behavior of MDA‑MB‑231 and SKOV3 cells .

Jo G, Jung S, Roh T, Yoon J, Lee J Mol Med Rep. 2024; 30(1).

PMID: 38757335 PMC: 11099723. DOI: 10.3892/mmr.2024.13238.

Haemostatic gene variations in cervical cancer-associated venous thrombosis: considerations for clinical strategies.

Neto B, Tavares V, Brito da Silva J, Liz-Pimenta J, Marques I, Salgado L J Thromb Thrombolysis. 2024; 57(5):815-827.

PMID: 38643313 DOI: 10.1007/s11239-024-02983-2.

References

Hughes M, Hayward C, Warkentin T, Horsewood P, Chorneyko K, Kelton J . Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. Blood. 2000; 96(1):188-94. View

Berckmans R, Nieuwland R, Boing A, Romijn F, Hack C, Sturk A . Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost. 2001; 85(4):639-46. View

Lwaleed B, Francis J, Chisholm M . Monocyte tissue factor levels in cancer patients. Saudi Med J. 2001; 21(8):722-9. View

Coussens L, Werb Z . Inflammation and cancer. Nature. 2002; 420(6917):860-7. PMC: 2803035. DOI: 10.1038/nature01322. View

Kanazawa S, Nomura S, Kuwana M, Muramatsu M, Yamaguchi K, Fukuhara S . Monocyte-derived microparticles may be a sign of vascular complication in patients with lung cancer. Lung Cancer. 2003; 39(2):145-9. DOI: 10.1016/s0169-5002(02)00441-5. View

Villmow T, Kemkes-Matthes B, Matzdorff A . Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes. Thromb Res. 2003; 108(2-3):139-45. DOI: 10.1016/s0049-3848(02)00354-7. View

Butenas S, Bouchard B, Brummel-Ziedins K, Parhami-Seren B, Mann K . Tissue factor activity in whole blood. Blood. 2004; 105(7):2764-70. DOI: 10.1182/blood-2004-09-3567. View

Kempton C, Hoffman M, Roberts H, Monroe D . Platelet heterogeneity: variation in coagulation complexes on platelet subpopulations. Arterioscler Thromb Vasc Biol. 2005; 25(4):861-6. DOI: 10.1161/01.ATV.0000155987.26583.9b. View

Arellano-Rodrigo E, Alvarez-Larran A, Reverter J, Villamor N, Colomer D, Cervantes F . Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica. 2006; 91(2):169-75. View

10.

Kalinkovich A, Tavor S, Avigdor A, Kahn J, Brill A, Petit I . Functional CXCR4-expressing microparticles and SDF-1 correlate with circulating acute myelogenous leukemia cells. Cancer Res. 2006; 66(22):11013-20. DOI: 10.1158/0008-5472.CAN-06-2006. View

11.

Tesselaar M, Romijn F, Van der Linden I, Prins F, Bertina R, Osanto S . Microparticle-associated tissue factor activity: a link between cancer and thrombosis?. J Thromb Haemost. 2006; 5(3):520-7. DOI: 10.1111/j.1538-7836.2007.02369.x. View

12.

Hron G, Kollars M, Weber H, Sagaster V, Quehenberger P, Eichinger S . Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost. 2007; 97(1):119-23. View

13.

Bae O, Lim K, Noh J, Chung S, Kim H, Lee C . Arsenite-enhanced procoagulant activity through phosphatidylserine exposure in platelets. Chem Res Toxicol. 2007; 20(12):1760-8. DOI: 10.1021/tx700159y. View

14.

Khorana A, Kuderer N, Culakova E, Lyman G, Francis C . Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008; 111(10):4902-7. PMC: 2384124. DOI: 10.1182/blood-2007-10-116327. View

15.

Wolberg A, Campbell R . Thrombin generation, fibrin clot formation and hemostasis. Transfus Apher Sci. 2008; 38(1):15-23. PMC: 2408736. DOI: 10.1016/j.transci.2007.12.005. View

16.

Davila M, Amirkhosravi A, Coll E, Desai H, Robles L, Colon J . Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J Thromb Haemost. 2008; 6(9):1517-24. DOI: 10.1111/j.1538-7836.2008.02987.x. View

17.

Nierodzik M, Plotkin A, Kajumo F, Karpatkin S . Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. J Clin Invest. 1991; 87(1):229-36. PMC: 295033. DOI: 10.1172/JCI114976. View

18.

Toth B, Nieuwland R, Liebhardt S, Ditsch N, Steinig K, Stieber P . Circulating microparticles in breast cancer patients: a comparative analysis with established biomarkers. Anticancer Res. 2008; 28(2A):1107-12. View

19.

Marchetti M, Castoldi E, Spronk H, Van Oerle R, Balducci D, Barbui T . Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood. 2008; 112(10):4061-8. DOI: 10.1182/blood-2008-06-164087. View

20.

Toth B, Liebhardt S, Steinig K, Ditsch N, Rank A, Bauerfeind I . Platelet-derived microparticles and coagulation activation in breast cancer patients. Thromb Haemost. 2008; 100(4):663-9. View